Introduction
Historically associated with antacid use, milk-alkali syndrome (MAS) is rising in incidence with the increased use of calcium carbonate for osteoporosis and chronic kidney disease (CKD). Early measurement of parathyroid hormone (PTH) helps distinguish MAS from primary hyperparathyroidism. Rebound hypocalcemia and hyperparathyroidism may be seen during treatment and are thought to be features unique to MAS. With increasing use of calcium carbonate in older persons, clinicians should remain vigilant for MAS in elderly patients presenting with hypercalcemia. We report a
